Filana Therapeutics (FLNA) Accounts Payables (2010 - 2023)

Filana Therapeutics has reported Accounts Payables for 14 years, with the latest figure at $10.3 million in Q2 2023.

• On a quarterly basis, Accounts Payables rose 117.28% year-over-year to $10.3 million in Q2 2023; TTM through Jun 2023 was $10.3 million, a 117.28% increase from a year earlier, with the FY2022 full-year figure at $4.0 million, down 43.63% from the prior year.
• Accounts Payables was $10.3 million for Q2 2023 at Filana Therapeutics, up from $8.2 million in the prior quarter.
• The five-year high for Accounts Payables was $10.3 million in Q2 2023, with the low at $340000.0 in Q3 2019.
• Average Accounts Payables over 5 years is $2.8 million, with a median of $1.4 million recorded in 2020.
• The sharpest annual moves came in 2021 and 2022: Accounts Payables surged 682.22% in 2021, then plunged 43.63% in 2022.
• Over 5 years, Accounts Payables stood at $453000.0 in 2019, then soared by 101.1% to $911000.0 in 2020, then soared by 682.22% to $7.1 million in 2021, then sank by 43.63% to $4.0 million in 2022, then jumped by 157.36% to $10.3 million in 2023.
• The last three Accounts Payables figures came in at $10.3 million (Q2 2023), $8.2 million (Q1 2023), and $4.0 million (Q4 2022), per Business Quant data.